199 related articles for article (PubMed ID: 34397868)
21. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
22. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC
Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic Thyroid Cancer: New Horizons and Challenges.
Maniakas A; Zafereo M; Cabanillas ME
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
[TBL] [Abstract][Full Text] [Related]
24. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
Lee NY; Riaz N; Wu V; Brinkman T; Tsai CJ; Zhi W; Fetten J; Ho A; Wong RJ; Ghossein R; Tuttle M; Fagin J; Pfister DG; Sherman E
Thyroid; 2022 Jul; 32(7):799-806. PubMed ID: 35521657
[No Abstract] [Full Text] [Related]
25. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
27. Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.
Liu TR; Xiao ZW; Xu HN; Long Z; Wei FQ; Zhuang SM; Sun XM; Xie LE; Mu JS; Yang AK; Zhang GP; Fan Y
PLoS One; 2016; 11(10):e0164840. PubMed ID: 27760217
[TBL] [Abstract][Full Text] [Related]
28. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.
Wendler J; Kroiss M; Gast K; Kreissl MC; Allelein S; Lichtenauer U; Blaser R; Spitzweg C; Fassnacht M; Schott M; Führer D; Tiedje V
Eur J Endocrinol; 2016 Dec; 175(6):521-529. PubMed ID: 27926471
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Management of Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Foote RL; Kasperbauer JL; Bible KC
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):269-284. PubMed ID: 30717908
[TBL] [Abstract][Full Text] [Related]
30. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
31. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
32. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic Thyroid Cancer Successfully Treated With Radiation and Immunotherapy: A Case Report.
Yang SR; Tsai MH; Hung CJ; Peng SL; Chiu NT; Huang YH; Tsai HJ
AACE Clin Case Rep; 2021; 7(5):299-302. PubMed ID: 34522768
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
[TBL] [Abstract][Full Text] [Related]
36. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
37. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
38. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
39. [Personalized approach to anaplastic thyroid carcinoma].
Wächter S; Bartsch DK; Maurer E
Chirurgie (Heidelb); 2024 Mar; 95(3):192-199. PubMed ID: 37973622
[TBL] [Abstract][Full Text] [Related]
40. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
